MBX · ISSUER CIK 1776111
MBX Biosciences, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 3 MBX Biosciences, Inc. insiders reported $0.00 of open-market purchases and $24K of sales on SEC Form 4.
↗3 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 1 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$24KInsider selling
−$24KNet open-market
Aug 5, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 5, 202616:57 | Aug 4, 2026 | MBX | Chief Medical Officer | S · Sell | $65.77 | −370 | 14,399 | -3% | −$24K | ||
| Aug 4, 202608:51 | Aug 3, 2026 | MBX | Chief Financial Officer | A · Grant | — | +28,000 | 28,000 | New | — | ||
| Aug 4, 202608:50 | Aug 3, 2026 | MBX | President and CEO, Director | A · Grant | — | +71,000 | 82,938 | +595% | — |